"10.1371_journal.pone.0029186","plos one","2012-01-03T00:00:00Z","Tracy R Glass; Margalida Rotger; Amalio Telenti; Laurent Decosterd; Chantal Csajka; Heiner C Bucher; Huldrych F GÃ¼nthard; Martin Rickenbach; Dunja Nicca; Bernard Hirschel; Enos Bernasconi; Gilles Wandeler; Manuel Battegay; Catia Marzolini; the Swiss HIV Cohort Study","Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Basel, Switzerland; Institute of Microbiology, University Hospital of Lausanne, Lausanne, Switzerland; Division of Clinical Pharmacology and Toxicology, University Hospital of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University of Zurich and University Hospital of Zurich, Zurich, Switzerland; Swiss HIV Cohort Data Center, University Hospital of Lausanne, Lausanne, Switzerland; Division of Infectious Diseases, Kantonsspital of St Gallen, St Gallen, Switzerland; Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland; Division of Infectious Diseases, Regional Hospital of Lugano, Lugano, Switzerland; Division of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland; Department of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland","Conceived and designed the experiments: TRG AT MB CM. Performed the experiments: TRG M. Rotger LD CC CM. Analyzed the data: TRG CM. Contributed reagents/materials/analysis tools: M. Rotger AT LD CC HCB HFG M. Rickenbach DN BH EB GW MB. Wrote the paper: TRG CM. Critical revision of the manuscript and approval: TRG M. Rotger AT LD CC HCB HFG M. Rickenbach DN BH EB GW MB CM.","The authors have read the journals policy and have the following conflicts: HCB has received travel grants, honoraria and unrestricted research grants from GlaxoSmithKline, Bristol-Myers-Squibb, Merck Sharp & Dohme, Gilead, Janssen, Roche, Abbott, Tibotec, Boehringer-Ingelheim and ViiV Healthcare. HFG has been an adviser and/or consultant for the following companies: GlaxoSmithKline, Abbott, Novartis, Boehringer Ingelheim, Roche, Tib tec and Bristol-Myers Squibb, and has received unrestricted research and educational grants from Roche, Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Tibotec and Merck Sharp & Dohme (integral financial support went to the institution). EB received honoraria or travel grants from the following pharmaceutical companies: Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, ViiV Healthcare, Merck Sharp & Dohme, Janssen. MB has received speakers honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme and Tibotec and has received unrestricted research grants from Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline and serves as a consultant for Boehringer Ingelheim Switzerland. TRG, MR, AT, LD, CC, MR, DN, BH, GW, and CM declare no competing interests. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","01","Tracy R Glass","TRG",15,FALSE,4,2,2,2,TRUE,TRUE,TRUE,9,"4;5;6;7;9;10;11;12;15",TRUE
